BAY1125976   Click here for help

GtoPdb Ligand ID: 10908

Synonyms: BAY-1125976 | Example 5 [WO2012136776A1]
Compound class: Synthetic organic
Comment: BAY1125976 is an allosteric inhibitor of AKT1 and AKT2 that is being developed by Bayer for oncology potential. It is claimed as example 5 in Bayer's patent WO2012136776A1 [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 99.3
Molecular weight 383.17
XLogP 3.82
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES NC(=O)c1ccc2n(n1)c(c1ccccc1)c(n2)c1ccc(cc1)C1(N)CCC1
Isomeric SMILES NC(=O)c1ccc2n(n1)c(c1ccccc1)c(n2)c1ccc(cc1)C1(N)CCC1
InChI InChI=1S/C23H21N5O/c24-22(29)18-11-12-19-26-20(21(28(19)27-18)16-5-2-1-3-6-16)15-7-9-17(10-8-15)23(25)13-4-14-23/h1-3,5-12H,4,13-14,25H2,(H2,24,29)
1. Bärfacker L, Scott W, Hägebarth A, Ince S, Rehwinkel H, Politz O, Neuhaus R, Briem H, Bömer U. (2012)
Imidazopyridazines as Akt kinase inhibitors.
Patent number: WO2012136776A1. Assignee: Bayer Pharma AG. Priority date: 07/04/2011. Publication date: 11/10/2012.
2. Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M et al.. (2019)
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.
Cancers (Basel), 11 (12). DOI: 10.3390/cancers11121987 [PMID:31835495]